Topical curcumin can inhibit deleterious effects of upper respiratory tract bacteria on human oropharyngeal cells in vitro: potential role for patients with cancer therapy induced mucositis?
OBJECTIVE
Curcumin exerts its anti-inflammatory activity via inhibition of nuclear factor κB. Oropharyngeal epithelia and residing bacteria closely interact in inflammation and infection. This in vitro model investigated the effects of curcumin on bacterial survival, adherence to, and invasion of upper respiratory tract epithelia, and studied its anti-inflammatory effect. We aimed to establish a model, which could offer insights into the host-pathogen interaction in cancer therapy induced mucositis.


METHODS
Moraxella catarrhalis (Mcat) and the oropharyngeal epithelial cell line Detroit 562 were used. Time-kill curves assessed the inhibition of bacterial growth and adherence assays and gentamicin protection assays determined the effect of curcumin-preincubated cells on bacterial adherence and invasion. Curcumin-mediated inhibition of pro-inflammatory activation by Mcat was determined via interleukin-8 concentrations in the supernatants. The synergistic role of secretory IgA (sIgA) on adherence was investigated.


RESULTS
Curcumin was bactericidal at concentrations >50 µM. Preincubation of Detroit cells for 60 min demonstrated that concentrations >100 µM inhibited bacterial adherence. Together with sIgA, curcumin inhibited adherence at concentrations ≥50 µM. Both 100 and 200 µM curcumin significantly inhibited Mcat cell invasion. Finally, curcumin inhibited Mcat-induced pro-inflammatory activation by strongly suppressing IL-8 release. At a concentration of 200 µM, 10 min of curcumin exposure inhibited IL-8 release significantly, and complete suppression required a pre-exposure time of ≥45 min.


CONCLUSIONS
Curcumin, in clinically relevant concentrations for topical use, displayed strong antibacterial effect against a facultative upper respiratory tract pathogen by inhibiting bacterial growth, adherence, invasion, and pro-inflammatory activation of upper respiratory tract epithelial cells in vitro.
Lüer
Sonja
S
Department of Pediatrics, University of Bern, Inselspital, 3010, Bern, Switzerland.
Troller
Rolf
R
Jetter
Marion
M
Spaniol
Violeta
V
Aebi
Christoph
C
D000287:Administration, Topical; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001422:Bacterial Adhesion / Q000187:drug effects; D002460:Cell Line; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects / Q000382:microbiology; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000008:administration & dosage*; D016209:Interleukin-8 / Q000378:metabolism; D001936:Moraxella catarrhalis / Q000187:drug effects*; D045828:Moraxellaceae Infections / Q000188:drug therapy / Q000382:microbiology; D009960:Oropharynx / Q000166:cytology / Q000382:microbiology; D013280:Stomatitis / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007071:Immunoglobulin A, Secretory; D016209:Interleukin-8; D003474:Curcumin
J Oncol. 2008;2008:907892
19259334
Clin Infect Dis. 2004 Jan 15;38(2):234-42
14699456
Am J Med. 2000 Sep;109(4):288-95
10996579
J Biol Chem. 2002 Mar 1;277(9):7438-46
11751883
J Infect Dis. 1988 Oct;158(4):761-5
3139777
EMBO J. 1998 Sep 1;17(17):5170-81
9724653
Pediatrics. 2006 May;117(5):1823-9
16651345
J Antimicrob Chemother. 2009 May;63 Suppl 1:i36-40
19372181
Int J Radiat Biol. 2004 Feb;80(2):177-82
15164799
Curr Opin Infect Dis. 2009 Jun;22(3):279-85
19405217
J Infect Dis. 2007 Oct 1;196(7):1080-7
17763332
J Infect Dis. 2009 Nov 15;200(10):1593-601
19835476
Int J Oral Surg. 1985 Oct;14(5):416-27
3932235
Eur J Clin Microbiol Infect Dis. 1996 Apr;15(4):291-6
8781879
J Biol Chem. 1995 Oct 20;270(42):24995-5000
7559628
J Infect Dis. 1993 Nov;168(5):1194-201
8228353
J Agric Food Chem. 2009 May 13;57(9):3765-70
19317462
Oral Oncol. 1998 Jan;34(1):39-43
9659518
Clin Infect Dis. 2009 Jul 1;49(1):124-31
19480579
Microbes Infect. 2008 Jan;10(1):3-11
18069032
Cancer. 2003 Oct 1;98(7):1531-9
14508842
Biochem J. 2008 Feb 15;410(1):147-55
17953519
Cancer Treat Rev. 2007 Aug;33(5):448-60
17507164
FEMS Immunol Med Microbiol. 2006 Mar;46(2):198-208
16487301
Cell Microbiol. 2007 Dec;9(12):2968-83
17764466
Biol Chem. 2005 May;386(5):481-90
15927892
Infect Immun. 1997 Nov;65(11):4367-77
9353007
Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L818-26
16399788
J Clin Immunol. 2007 Jan;27(1):19-35
17211725
Lancet. 2004 Feb 7;363(9407):465-73
14962529
Leukemia. 2004 Feb;18(2):276-84
14671640
J Infect Dis. 1994 Jun;169(6):1312-7
8195609
Eur Respir J. 2008 Apr;31(4):725-35
18184679
Infect Immun. 1998 Jul;66(7):3113-9
9632574
Cell Microbiol. 2007 Mar;9(3):694-707
17054439